Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 15/20 | 0.71 |
| ▸ | PPARG | P37231 | 10/20 | 0.71 |
| ▸ | PPARA | Q07869 | 6/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | PPARD | Q03181 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226864 | 0.91 | NR1H4 (0.77) | NR1H4PPARGPPARAPPARDTP53 | |
| SCHEMBL29903436 | 0.90 | NR1H4 (0.74) | NR1H4PPARGPPARAPPARD | |
| SCHEMBL5223825 | 0.88 | NR1H4 (0.71) | NR1H4PPARGPPARARXFP1PPARD | |
| SCHEMBL5222902 | 0.88 | NR1H4 (0.67) | NR1H4PPARGPPARAPPARD | |
| SCHEMBL5226687 | 0.88 | NPC1 (0.74) | NR1H4PPARGPPARARXFP1PPARD | |
| SCHEMBL5223218 | 0.86 | NR1H4 (0.73) | NR1H4PPARGPPARARXFP1PPARD | |
| SCHEMBL7291713 | 0.86 | NPC1 (0.79) | NR1H4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1687867 | 0.86 | NPC1 (0.79) | NR1H4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7293746 | 0.86 | NPC1 (0.79) | NR1H4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5227095 | 0.84 | NR1H4 (0.78) | NR1H4PPARGPPARARXFP1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1014962-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2007-06-27 | — | — | EP | disclosed |
| US-6605626-B2 | Benzamide inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-08-12 | — | — | US | disclosed |
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | BEIGHT DOUGLAS WADE (US) | 2002-08-29 | — | — | US | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120007-A1 | Benzamide inhibitors of factor Xa | TFPI, F11, F12 | NR1H4 2304/4885PPARG 2764/4885PPARA 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.